Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for OncoSil Medical's OCF Margin % or its related term are showing as below:
ASX:OSL'
s OCF Margin % Range Over the Past 10 Years
Min: -4357.76 Med: -3075 Max: -1030.06
Current: -863.41
During the past 13 years, the highest OCF Margin % of OncoSil Medical was -1030.06%. The lowest was -4357.76%. And the median was -3075.00%.
ASX:OSL's OCF Margin % is ranked worse than 94.36% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: 5.785
vs ASX:OSL: -863.41
OncoSil Medical OCF Margin % Related Terms
OncoSil Medical OCF Margin % Historical Data
* Premium members only.
The historical data trend for OncoSil Medical's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, OncoSil Medical's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoSil Medical OCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, OncoSil Medical's OCF Margin % distribution charts can be found below:
* The bar in red indicates where OncoSil Medical's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoSil Medical (ASX:OSL) has a OCF Margin % of -889.02% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on OncoSil Medical and its competitors. According to the industry distribution chart, OncoSil Medical ranks #770 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 94.4%.
Is OncoSil Medical's OCF Margin % too high?
OncoSil Medical's current OCF Margin % is -889.02%. Based on the distribution chart, OncoSil Medical ranks #770 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, OncoSil Medical has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OncoSil Medical's OCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, OncoSil Medical ranks #770 out of 816 companies for OCF Margin %. This places OncoSil Medical in the lower half of its industry. The industry median OCF Margin % is 5.79. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Devices & Instruments company?
The median OCF Margin % among Medical Devices & Instruments companies is 5.79, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on OncoSil Medical and its competitors. For the Medical Devices & Instruments industry, the median OCF Margin % is 5.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OncoSil Medical's current OCF Margin % is -889.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoSil Medical stock overvalued right now?
Based on GuruFocus' analysis, OncoSil Medical (ASX:OSL) is currently considered Possible Value Trap. The stock's GF Value™ is A$2.90, compared to a current price of A$1.38 — trading 52.6% below its estimated fair value. The current OCF Margin % is -889.02%. OncoSil Medical's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For OncoSil Medical (ASX:OSL), the current OCF Margin % is -889.02% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OncoSil Medical (ASX:OSL) Overvalued in 2026?
Based on GuruFocus' analysis, OncoSil Medical stock appears to be undervalued.
The current stock price of A$1.38 is trading 52.6% below its estimated GF Value™ of A$2.90.
GuruFocus considers OncoSil Medical to be Possible Value Trap.
Key valuation signals for ASX:OSL:
OCF Margin %: -889.02%
GF Value™: A$2.90 vs. price of A$1.38 (52.6% below fair value)
No single metric tells the full story. See the ASX:OSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.
48GF Score
Get the complete analysis for ASX:OSL
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:OSL has been successfully added to your 
